Management of Non-metastatic castrate-resistant prostate cancer

P. Mourmouris, Christos Papachristou, Titos Markopoulos, Marinos Mperdempes, N. Kostakopoulos, L. Lazarou, M. Tuna, A. Skolarikos
{"title":"Management of Non-metastatic castrate-resistant prostate cancer","authors":"P. Mourmouris, Christos Papachristou, Titos Markopoulos, Marinos Mperdempes, N. Kostakopoulos, L. Lazarou, M. Tuna, A. Skolarikos","doi":"10.19264/HJ.V30I1.224","DOIUrl":null,"url":null,"abstract":"When castration resistance is established, it is essential to rule out the presence of metastases or micrometastases by optimizing the use of imaging techniques. If non-metastastic castrate resistant prostate cancer diagnosis is confirmed the physician is in front of a difficult decision: to treat it or not and if not, how he can follow up his patient. In practice, patients awareness of their PSA levels and pressure to act upon any increase of PSA influence management irrespective of physical or radiographic findings. This highlights the need to have more accurate assessment of nmCRPC severity and the risk of progression. We review the literature about this ambiguous entity and we summarize all the available data for it’s management.","PeriodicalId":185530,"journal":{"name":"Hellenic Urology","volume":"65 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hellenic Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19264/HJ.V30I1.224","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

When castration resistance is established, it is essential to rule out the presence of metastases or micrometastases by optimizing the use of imaging techniques. If non-metastastic castrate resistant prostate cancer diagnosis is confirmed the physician is in front of a difficult decision: to treat it or not and if not, how he can follow up his patient. In practice, patients awareness of their PSA levels and pressure to act upon any increase of PSA influence management irrespective of physical or radiographic findings. This highlights the need to have more accurate assessment of nmCRPC severity and the risk of progression. We review the literature about this ambiguous entity and we summarize all the available data for it’s management.
非转移性去势抵抗性前列腺癌的治疗
当去势抵抗建立时,必须通过优化成像技术的使用来排除转移或微转移的存在。如果非转移性去势抵抗性前列腺癌的诊断得到证实,医生就面临着一个艰难的决定:是否治疗,如果不治疗,他该如何跟进他的病人。在实践中,患者意识到自己的PSA水平,并有压力采取任何PSA影响管理的增加,而不考虑物理或放射检查结果。这强调了对nmCRPC严重程度和进展风险进行更准确评估的必要性。我们回顾了有关这一模糊实体的文献,并总结了所有可用于其管理的数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信